|Mr. Jeffrey F. Eisenberg||CEO & Director||318.33k||N/A||1966|
|Mr. James F. Parslow||CFO, COO & Corp. Sec.||287.6k||N/A||1965|
|Dr. Curtis A. Lockshin||Chief Scientific Officer||259.58k||N/A||1960|
Xenetic Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, research, and development of next-generation biologic drugs and novel orphan oncology therapeutics. The company's lead investigational product candidate is oncology therapeutic XBIO-101 (sodium cridanimod) for the treatment of progestin resistant endometrial cancer. It is also developing ErepoXen, a drug using PolyXen platform technology for the treatment of anemia in chronic kidney disease patients. The company has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Xenetic Biosciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.